Education
About Us
Working with TipRanks
Follow Us
CSPC Pharmaceutical Group Limited (HK:1093)
:1093
1093 Analyst Ratings
Moderate Buy
13 Buy
2 Hold
3 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
1093 Stock 12 Month Forecast
Average Price Target
HK$10.82
▲(31.90% Upside)
| Highest Price TargetHK$17.40 | Average Price TargetHK$10.82 | Lowest Price TargetHK$6.60 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Macquarie
HK$12.9→HK$12.4
Buy
51.22%
Upside
Reiterated
11/25/25
CMB International Securities
HK$12.11→HK$11.05
Buy
34.76%
Upside
Reiterated
11/21/25
CSPC Pharmaceutical Group's Strategic Growth and Financial Outlook Reinforce Buy RatingWe expect CSPC’s drug sales to remain stable in 4Q25E. On the cost side, the selling expense ratio shrank significantly from 29.2% in 9M24 to 24.1% in 9M25. R&D investment remained a priority, with R&D expenses rising 7.9% R&D expense ratio). Attributable net profit was RMB3.5bn in 9M25, representing a 7.1% YoY decline.
Unknown Analyst
Bank of ChinaNot Ranked
Bank of China
HK$8.5
Sell
3.66%
Upside
Reiterated
11/21/25
Unknown Analyst
BOCOM International Holdings CompanyNot Ranked
BOCOM International Holdings Company
HK$7.3
Hold
-10.98%
Downside
Reiterated
11/21/25
Unknown Analyst
CLSANot Ranked
CLSA
HK$17.4
Buy
112.20%
Upside
Reiterated
11/21/25
Nomura
HK$9.11
Buy
11.10%
Upside
Reiterated
11/20/25
Citi
HK$12.1
Buy
47.56%
Upside
Reiterated
11/20/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Macquarie
HK$12.9→HK$12.4
Buy
51.22%
Upside
Reiterated
11/25/25
CMB International Securities
HK$12.11→HK$11.05
Buy
34.76%
Upside
Reiterated
11/21/25
CSPC Pharmaceutical Group's Strategic Growth and Financial Outlook Reinforce Buy RatingWe expect CSPC’s drug sales to remain stable in 4Q25E. On the cost side, the selling expense ratio shrank significantly from 29.2% in 9M24 to 24.1% in 9M25. R&D investment remained a priority, with R&D expenses rising 7.9% R&D expense ratio). Attributable net profit was RMB3.5bn in 9M25, representing a 7.1% YoY decline.
Unknown Analyst
Bank of ChinaNot Ranked
Bank of China
HK$8.5
Sell
3.66%
Upside
Reiterated
11/21/25
Unknown Analyst
BOCOM International Holdings CompanyNot Ranked
BOCOM International Holdings Company
HK$7.3
Hold
-10.98%
Downside
Reiterated
11/21/25
Unknown Analyst
CLSANot Ranked
CLSA
HK$17.4
Buy
112.20%
Upside
Reiterated
11/21/25
Nomura
HK$9.11
Buy
11.10%
Upside
Reiterated
11/20/25
Citi
HK$12.1
Buy
47.56%
Upside
Reiterated
11/20/25
Best Analysts Covering CSPC Pharmaceutical Group
1 Month
xxx
Success Rate
7/12 ratings generated profit
Average Return
+1.57%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +1.57% per trade.
3 Months
xxx
Success Rate
8/12 ratings generated profit
Average Return
+10.88%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +10.88% per trade.
1 Year
Success Rate
8/12 ratings generated profit
Average Return
+21.04%
reiterated a buy rating last month
Copying Jill Wu's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +21.04% per trade.
2 Years
xxx
Success Rate
11/12 ratings generated profit
Average Return
+36.44%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 91.67% of your transactions generating a profit, with an average return of +36.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
1093 Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
13
14
10
14
12
Buy
1
0
0
0
0
Hold
4
3
5
4
3
Sell
5
5
5
4
4
Strong Sell
0
0
0
0
0
total
23
22
20
22
19
Each month's total comprises the sum of three months' worth of ratings.
1093 Financial Forecast
1093 Stock Forecast FAQ
What is HK:1093’s average 12-month price target, according to analysts?
Based on analyst ratings, CSPC Pharmaceutical Group Limited’s 12-month average price target is 10.82.
What is HK:1093’s upside potential, based on the analysts’ average price target?
CSPC Pharmaceutical Group Limited has 31.90% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CSPC Pharmaceutical Group Limited a Buy, Sell or Hold?
CSPC Pharmaceutical Group Limited has a consensus rating of Moderate Buy, which is based on 13 buy ratings, 2 hold ratings and 3 sell ratings.
What is CSPC Pharmaceutical Group Limited’s share price target?
The average share price target for CSPC Pharmaceutical Group Limited is 10.82. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$17.40 ,and the lowest forecast is HK$6.60. The average share price target represents 31.90% Increase from the current price of HK$8.2.
The highest analyst share price target is HK$17.40 ,and the lowest forecast is HK$6.60. The average share price target represents 31.90% Increase from the current price of HK$8.2.
What do analysts say about CSPC Pharmaceutical Group Limited?
CSPC Pharmaceutical Group Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of CSPC Pharmaceutical Group Limited?
To buy shares of HK:1093, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.